Patents by Inventor Dietmar Reusch
Dietmar Reusch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230227564Abstract: The invention provides an antibody comprising human IgG1 or IgG3 heavy chain constant domains that are glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is at least 99%, and in addition the amount of NGNA is 1% or less and/or the amount of N-terminal alpha 1,3 galactose is 1% or less, and uses thereof.Type: ApplicationFiled: March 23, 2023Publication date: July 20, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Silke Hansen, Klaus-Peter Kuenkele, Dietmar Reusch, Ralf Schumacher
-
Patent number: 11673958Abstract: The invention provides an antibody comprising human IgG1 or IgG3 heavy chain constant domains that are glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is at least 99%, and in addition the amount of NGNA is 1% or less and/or the amount of N-terminal alpha 1,3 galactose is 1% or less, and uses thereof.Type: GrantFiled: March 3, 2014Date of Patent: June 13, 2023Assignee: Hoffmann-La Roche Inc.Inventors: Silke Hansen, Klaus-Peter Kuenkele, Dietmar Reusch, Ralf Schumacher
-
Publication number: 20200325245Abstract: The present invention relates to galactoengineered recombinant antibodies of IgG1 isotype, methods for the production of said antibodies and uses thereof.Type: ApplicationFiled: June 25, 2020Publication date: October 15, 2020Applicants: Genentech, Inc., Hoffmann-La Roche Inc.Inventors: Sebastian Malik, Dietmar Reusch, Alfred Schnüriger, Max L. Tejada, Marco Thomann
-
Publication number: 20170253661Abstract: The present invention relates to galactoengineered recombinant antibodies of IgG1 isotype, methods for the production of said antibodies and uses thereof.Type: ApplicationFiled: March 10, 2017Publication date: September 7, 2017Applicants: Hoffmann-La Roche Inc., Genentech, Inc.Inventors: Sebastian Malik, Dietmar Reusch, Alfred Schnüriger, Max L Tejada, Marco Thomann
-
Patent number: 9365881Abstract: The current invention comprises a method for producing an immunoglobulin or immunoglobulin fragment or immunoglobulin fusion with G1 glycostructure comprising incubating with a galactosyltransferase, a sialyltransferase, a beta-1,4-galactosidase and a sialidase, whereby the galactosyltransferase is added in more than one aliquot during the incubating.Type: GrantFiled: October 2, 2012Date of Patent: June 14, 2016Assignee: Hoffmann-La Roche Inc.Inventors: Martina Hueller, Dietmar Reusch
-
Publication number: 20140234899Abstract: The current invention comprises a method for producing an immunoglobulin or immunoglobulin fragment or immunoglobulin fusion with G1 glycostructure comprising incubating with a galactosyltransferase, a sialyltransferase, a beta-1,4-galactosidase and a sialidase, whereby the galactosyltransferase is added in more than one aliquot during the incubating.Type: ApplicationFiled: October 2, 2012Publication date: August 21, 2014Applicant: HOFFMANN-LA ROCHE INC.Inventors: Martina Hueller, Dietmar Reusch
-
Publication number: 20140193404Abstract: The invention provides an antibody comprising human IgG1 or IgG3 heavy chain constant domains that are glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is at least 99%, and in addition the amount of NGNA is 1% or less and/or the amount of N-terminal alpha 1,3 galactose is 1% or less, and uses thereof.Type: ApplicationFiled: March 3, 2014Publication date: July 10, 2014Applicant: Hoffmann-La Roche Inc.Inventors: Silke Hansen, Klaus-Peter Kuenkele, Dietmar Reusch, Ralf Schumacher
-
Patent number: 8703919Abstract: The invention provides an antibody comprising human IgG1 or IgG3 heavy chain constant domains that are glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is at least 99%, and in addition the amount of NGNA is 1% or less and/or the amount of N-terminal alpha 1,3 galactose is 1% or less, and uses thereof.Type: GrantFiled: November 17, 2011Date of Patent: April 22, 2014Assignee: Hoffmann-La Roche Inc.Inventors: Silke Hansen, Klaus-Peter Kuenkele, Dietmar Reusch, Ralf Schumacher
-
Patent number: 8524470Abstract: The current invention comprises a method for producing an immunoglobulin or immunoglobulin fragment with defined glycostructure comprising the following steps: a) providing an affinity chromatography column eluate containing the immunoglobulin or immunoglobulin fragment, b) incubating the affinity chromatography column eluate with (?1,3)galactosidase of plant origin, e.g. from green coffee beans (EC 3.2.1.22), c) applying the incubated affinity chromatography column eluate to a protein A chromatography material and recovering the immunoglobulin or immunoglobulin fragment from the protein A chromatography material and thereby producing an immunoglobulin or immunoglobulin fragment with defined glycostructure.Type: GrantFiled: July 28, 2010Date of Patent: September 3, 2013Assignee: Hoffman-La Roche, Inc.Inventors: Markus Haberger, Christine Jung, Dietmar Reusch
-
Publication number: 20120172255Abstract: Herein is reported a method for the determination of the glycosylation of an immunoglobulin with electrospray mass spectrometry but without the need for a chromatographic purification step after the digestion of the immunoglobulin and prior to the mass spectrometric analysis.Type: ApplicationFiled: September 3, 2010Publication date: July 5, 2012Applicant: HOFFMANN-LA ROCHE, INC,Inventors: Markus Haberger, Dietmar Reusch, Maurice Selman, Manfred Wuhrer
-
Publication number: 20120129216Abstract: The current invention comprises a method for producing an immunoglobulin or immunoglobulin fragment with defined glycostructure comprising the following steps: a) providing an affinity chromatography column eluate containing the immunoglobulin or immunoglobulin fragment, b) incubating the affinity chromatography column eluate with (?1,3)galactosidase of plant origin, e.g. from green coffee beans (EC 3.2.1.22), c) applying the incubated affinity chromatography column eluate to a protein A chromatography material and recovering the immunoglobulin or immunoglobulin fragment from the protein A chromatography material and thereby producing an immunoglobulin or immunoglobulin fragment with defined glycostructure.Type: ApplicationFiled: July 28, 2010Publication date: May 24, 2012Inventors: Markus Haberger, Christine Jung, Dietmar Reusch
-
Publication number: 20120128664Abstract: The invention provides an antibody comprising human IgG1 or IgG3 heavy chain constant domains that are glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is at least 99%, and in addition the amount of NGNA is 1% or less and/or the amount of N-terminal alpha 1,3 galactose is 1% or less, and uses thereof.Type: ApplicationFiled: November 17, 2011Publication date: May 24, 2012Inventors: Silke Hansen, Klaus-Peter Kuenkele, Dietmar Reusch, Ralf Schumacher
-
Publication number: 20110117601Abstract: The present invention provides a method for the production of a glycosylated heterologous polypeptide comprising the steps of obtaining a sample from a crude fermentation broth, incubation of the sample with magnetic affinity beads, releasing glycans from the immobilized glycosylated polypeptides, measuring a glycosylation profile, comparing the glycosylation profile with a desired glycosylation profile of the recombinant glycosylated polypeptide, modifying the culture conditions in accordance to the glycosylation profile obtained, and repeating the process in order to obtain a glycosylated heterologous polypeptide with the desired glycosylation profile. With a similar method diagnostic markers can be identified and quantified.Type: ApplicationFiled: August 20, 2008Publication date: May 19, 2011Inventors: Markus Haberger, Dietmar Reusch
-
Publication number: 20100322927Abstract: The invention provides an antibody comprising human IgG1 or IgG3 heavy chain constant domains that are glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is at least 99%, and in addition the amount of NGNA is 1% or less and/or the amount of N-terminal alpha 1,3 galactose is 1% or less, and uses thereof.Type: ApplicationFiled: September 1, 2010Publication date: December 23, 2010Inventors: Silke Hansen, Klaus-Peter Kuenkele, Dietmar Reusch, Ralf Schumacher
-
Patent number: 7846724Abstract: The invention provides an antibody comprising human IgG1 or IgG3 heavy chain constant domains that are glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is at least 99%, and in addition the amount of NGNA is 1% or less and/or the amount of N-terminal alpha 1,3 galactose is 1% or less, and uses thereof.Type: GrantFiled: April 5, 2007Date of Patent: December 7, 2010Assignee: Hoffmann-La Roche Inc.Inventors: Silke Hansen, Klaus-Peter Kuenkele, Dietmar Reusch, Ralf Schumacher
-
Publication number: 20080014203Abstract: An antibody binding to IGF-IR, being of human IgG1 or IgG3 type and being glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is at least 98%, and in addition the amount of NGNA is 1% or less and/or the amount of N-terminal alpha-1,3-galactose is 1% or less has improved properties in antitumor therapy.Type: ApplicationFiled: April 5, 2007Publication date: January 17, 2008Inventors: Silke Hansen, Klaus-Peter Kuenkele, Dietmar Reusch, Ralf Schumacher
-
Publication number: 20070248600Abstract: The invention provides an antibody comprising human IgG1 or IgG3 heavy chain constant domains that are glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is at least 99%, and in addition the amount of NGNA is 1% or less and/or the amount of N-terminal alpha 1,3 galactose is 1% or less, and uses thereof.Type: ApplicationFiled: April 5, 2007Publication date: October 25, 2007Inventors: Silke Hansen, Klaus-Peter Kuenkele, Dietmar Reusch, Ralf Schumacher